DOCSLIB.ORG

Federal Register/Vol. 86, No. 75/Wednesday, April 21, 2021

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Federal Register/Vol. 86, No. 75/Wednesday, April 21, 2021 20738 Federal Register / Vol. 86, No. 75 / Wednesday, April 21, 2021 / Notices Drug Controlled substance code Schedule Etorphine HCl .......................................................................................................................................................................... 9059 II Dihydrocodeine ........................................................................................................................................................................ 9120 II Diphenoxylate .......................................................................................................................................................................... 9170 II Ecgonine .................................................................................................................................................................................. 9180 II Ethylmorphine .......................................................................................................................................................................... 9190 II Levomethorphan ...................................................................................................................................................................... 9210 II Levorphanol ............................................................................................................................................................................. 9220 II Isomethadone .......................................................................................................................................................................... 9226 II Meperidine ............................................................................................................................................................................... 9230 II Meperidine intermediate–A ...................................................................................................................................................... 9232 II Meperidine intermediate–B ...................................................................................................................................................... 9233 II Meperidine intermediate–C ..................................................................................................................................................... 9234 II Metazocine .............................................................................................................................................................................. 9240 II Oliceridine (N-[(3-methoxythiophen-2yl)methyl] ({2-[9r)-9-(pyridin-2-yl)-6-oxaspiro [4.5]decan-9-yl]ethyl{time})amine fu- 9245 II marate). Metopon ................................................................................................................................................................................... 9260 II Dextropropoxyphene, bulk (non-dosage forms) ...................................................................................................................... 9273 II Dihydroetorphine ..................................................................................................................................................................... 9334 II Opium tincture ......................................................................................................................................................................... 9630 II Opium, powdered .................................................................................................................................................................... 9639 II Opium, granulated ................................................................................................................................................................... 9640 II Noroxymorphone ..................................................................................................................................................................... 9668 II Phenazocine ............................................................................................................................................................................ 9715 II Thiafentanil .............................................................................................................................................................................. 9729 II Piminodine ............................................................................................................................................................................... 9730 II Racemethorphan ..................................................................................................................................................................... 9732 II Racemorphan .......................................................................................................................................................................... 9733 II Alfentanil .................................................................................................................................................................................. 9737 II Remifentanil ............................................................................................................................................................................. 9739 II Sufentanil ................................................................................................................................................................................. 9740 II Carfentanil ............................................................................................................................................................................... 9743 II Tapentadol ............................................................................................................................................................................... 9780 II Bezitramide .............................................................................................................................................................................. 9800 II Moramide-intermediate ............................................................................................................................................................ 9802 II The company plans to import small DEPARTMENT OF JUSTICE 22152. All requests for a hearing must quantities of the listed controlled be sent to: Drug Enforcement substances for the National Institute on Drug Enforcement Administration Administration, Attn: Administrator, Drug Abuse for research activities. The [Docket No. DEA–822] 8701 Morrissette Drive, Springfield, company plans to import analytical Virginia 22152. All requests for a reference standards for distribution to Importer of Controlled Substances hearing should also be sent to: (1) Drug its customers for research and analytical Application: Scottsdale Research Enforcement Administration, Attn: purposes. Institute Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and Approval of permit applications will AGENCY: Drug Enforcement (2) Drug Enforcement Administration, occur only when the registrant’s Administration, Justice. Attn: DEA Federal Register business activity is consistent with what ACTION: Notice of application. Representative/DPW, 8701 Morrissette is authorized under 21 U.S.C. 952(a)(2). SUMMARY: Drive, Springfield, Virginia 22152. Authorization will not extend to the Scottsdale Research Institute has applied to be registered as an SUPPLEMENTARY INFORMATION: In import of Food and Drug importer of basic class(es) of controlled accordance with 21 CFR 1301.34(a), this Administration-approved or non- substance(s). Refer to SUPPLEMENTAL is notice that on January 28, 2021, approved finished dosage forms for INFORMATION listed below for further Scottsdale Research Institute, 5436 East commercial sale. drug information. Tapekim Road, Cave Creek, Arizona William T. McDermott, DATES: Registered bulk manufacturers of 85331, applied to be registered as an Assistant Administrator. the affected basic class(es), and importer of the following basic class(es) of controlled substance(s): [FR Doc. 2021–08166 Filed 4–20–21; 8:45 am] applicants therefore, may file written comments on or objections to the BILLING CODE P issuance of the proposed registration on Controlled substance Drug Schedule or before May 21, 2021. Such persons code may also file a written request for a Marihuana ........................ 7360 I hearing on the application on or before Tetrahydrocannabinols .... 7370 I May 21, 2021. Psilocybin ........................ 7437 I ADDRESSES: Written comments should Psilocyn ........................... 7438 I be sent to: Drug Enforcement Administration, Attention: DEA Federal The company plans to import Register Representative/DPW, 8701 Marijuana (7360) and Morrissette Drive, Springfield, Virginia Tetrahydrocannabinols (7370) as VerDate Sep<11>2014 18:12 Apr 20, 2021 Jkt 253001 PO 00000 Frm 00087 Fmt 4703 Sfmt 4703 E:\FR\FM\21APN1.SGM 21APN1 khammond on DSKJM1Z7X2PROD with NOTICES Federal Register / Vol. 86, No. 75 / Wednesday, April 21, 2021 / Notices 20739 flowering plants to support analytical Department of Justice, Office of Privacy However, JUSTICE/JMD–025 covers purposes, research, and the and Civil Liberties, ATTN: Privacy additional records—specifically records manufacturing of dosage forms for Analyst, Two Constitution Square collected in response to COVID–19, a clinical
Load more

Recommended publications
  • INVESTIGATION of NATURAL PRODUCT SCAFFOLDS for the DEVELOPMENT of OPIOID RECEPTOR LIGANDS by Katherine M
    INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS By Katherine M. Prevatt-Smith Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. _________________________________ Chairperson: Dr. Thomas E. Prisinzano _________________________________ Dr. Brian S. J. Blagg _________________________________ Dr. Michael F. Rafferty _________________________________ Dr. Paul R. Hanson _________________________________ Dr. Susan M. Lunte Date Defended: July 18, 2012 The Dissertation Committee for Katherine M. Prevatt-Smith certifies that this is the approved version of the following dissertation: INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS _________________________________ Chairperson: Dr. Thomas E. Prisinzano Date approved: July 18, 2012 ii ABSTRACT Kappa opioid (KOP) receptors have been suggested as an alternative target to the mu opioid (MOP) receptor for the treatment of pain because KOP activation is associated with fewer negative side-effects (respiratory depression, constipation, tolerance, and dependence). The KOP receptor has also been implicated in several abuse-related effects in the central nervous system (CNS). KOP ligands have been investigated as pharmacotherapies for drug abuse; KOP agonists have been shown to modulate dopamine concentrations in the CNS as well as attenuate the self-administration of cocaine in a variety of species, and KOP antagonists have potential in the treatment of relapse. One drawback of current opioid ligand investigation is that many compounds are based on the morphine scaffold and thus have similar properties, both positive and negative, to the parent molecule. Thus there is increasing need to discover new chemical scaffolds with opioid receptor activity.
    [Show full text]
  • SENATE BILL No. 52
    As Amended by Senate Committee Session of 2017 SENATE BILL No. 52 By Committee on Public Health and Welfare 1-20 1 AN ACT concerning the uniform controlled substances act; relating to 2 substances included in schedules I, II and V; amending K.S.A. 2016 3 Supp. 65-4105, 65-4107 and 65-4113 and repealing the existing 4 sections. 5 6 Be it enacted by the Legislature of the State of Kansas: 7 Section 1. K.S.A. 2016 Supp. 65-4105 is hereby amended to read as 8 follows: 65-4105. (a) The controlled substances listed in this section are 9 included in schedule I and the number set forth opposite each drug or 10 substance is the DEA controlled substances code which has been assigned 11 to it. 12 (b) Any of the following opiates, including their isomers, esters, 13 ethers, salts, and salts of isomers, esters and ethers, unless specifically 14 excepted, whenever the existence of these isomers, esters, ethers and salts 15 is possible within the specific chemical designation: 16 (1) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)- 17 N-phenylacetamide)......................................................................9821 18 (2) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4- 19 piperidinyl]-N-phenylacetamide)..................................................9815 20 (3) Acetylmethadol.............................................................................9601 21 (4) AH-7921 (3.4-dichloro-N-[(1- 22 dimethylaminocyclohexylmethyl]benzamide)...............................9551 23 (4)(5) Allylprodine...........................................................................9602
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Drugs of Abuseon September Archived 13-10048 No
    U.S. DEPARTMENT OF JUSTICE DRUG ENFORCEMENT ADMINISTRATION WWW.DEA.GOV 9, 2014 on September archived 13-10048 No. v. Stewart, in U.S. cited Drugs of2011 Abuse EDITION A DEA RESOURCE GUIDE V. Narcotics WHAT ARE NARCOTICS? Also known as “opioids,” the term "narcotic" comes from the Greek word for “stupor” and originally referred to a variety of substances that dulled the senses and relieved pain. Though some people still refer to all drugs as “narcot- ics,” today “narcotic” refers to opium, opium derivatives, and their semi-synthetic substitutes. A more current term for these drugs, with less uncertainty regarding its meaning, is “opioid.” Examples include the illicit drug heroin and pharmaceutical drugs like OxyContin®, Vicodin®, codeine, morphine, methadone and fentanyl. WHAT IS THEIR ORIGIN? The poppy papaver somniferum is the source for all natural opioids, whereas synthetic opioids are made entirely in a lab and include meperidine, fentanyl, and methadone. Semi-synthetic opioids are synthesized from naturally occurring opium products, such as morphine and codeine, and include heroin, oxycodone, hydrocodone, and hydromorphone. Teens can obtain narcotics from friends, family members, medicine cabinets, pharmacies, nursing 2014 homes, hospitals, hospices, doctors, and the Internet. 9, on September archived 13-10048 No. v. Stewart, in U.S. cited What are common street names? Street names for various narcotics/opioids include: ➔ Hillbilly Heroin, Lean or Purple Drank, OC, Ox, Oxy, Oxycotton, Sippin Syrup What are their forms? Narcotics/opioids come in various forms including: ➔ T ablets, capsules, skin patches, powder, chunks in varying colors (from white to shades of brown and black), liquid form for oral use and injection, syrups, suppositories, lollipops How are they abused? ➔ Narcotics/opioids can be swallowed, smoked, sniffed, or injected.
    [Show full text]
  • Introduced B.,Byhansen, 16
    LB301 LB301 2021 2021 LEGISLATURE OF NEBRASKA ONE HUNDRED SEVENTH LEGISLATURE FIRST SESSION LEGISLATIVE BILL 301 Introduced by Hansen, B., 16. Read first time January 12, 2021 Committee: Judiciary 1 A BILL FOR AN ACT relating to the Uniform Controlled Substances Act; to 2 amend sections 28-401, 28-405, and 28-416, Revised Statutes 3 Cumulative Supplement, 2020; to redefine terms; to change drug 4 schedules and adopt federal drug provisions; to change a penalty 5 provision; and to repeal the original sections. 6 Be it enacted by the people of the State of Nebraska, -1- LB301 LB301 2021 2021 1 Section 1. Section 28-401, Revised Statutes Cumulative Supplement, 2 2020, is amended to read: 3 28-401 As used in the Uniform Controlled Substances Act, unless the 4 context otherwise requires: 5 (1) Administer means to directly apply a controlled substance by 6 injection, inhalation, ingestion, or any other means to the body of a 7 patient or research subject; 8 (2) Agent means an authorized person who acts on behalf of or at the 9 direction of another person but does not include a common or contract 10 carrier, public warehouse keeper, or employee of a carrier or warehouse 11 keeper; 12 (3) Administration means the Drug Enforcement Administration of the 13 United States Department of Justice; 14 (4) Controlled substance means a drug, biological, substance, or 15 immediate precursor in Schedules I through V of section 28-405. 16 Controlled substance does not include distilled spirits, wine, malt 17 beverages, tobacco, hemp, or any nonnarcotic substance if such substance 18 may, under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C.
    [Show full text]
  • 16.19.20 Nmac 1 Title 16 Occupational And
    TITLE 16 OCCUPATIONAL AND PROFESSIONAL LICENSING CHAPTER 19 PHARMACISTS PART 20 CONTROLLED SUBSTANCES 16.19.20.1 ISSUING AGENCY: Regulation and Licensing Department - Board of Pharmacy. [16.19.20.1 NMAC - Rp 16.19.20.1 NMAC, 06-26-2018] 16.19.20.2 SCOPE: All persons or entities that manufacture, distribute, dispense, administer, prescribe, deliver, analyze, or conduct research using controlled substances. [16.19.20.2 NMAC - Rp 16.19.20.2 NMAC, 06-26-2018] 16.19.20.3 STATUTORY AUTHORITY: Section 30-31-11 of the Controlled Substances Act, 30-31-1 through 30-31-42 NMSA 1978, authorizes the board of pharmacy to promulgate regulations and charge reasonable fees for the registration and control of the manufacture, distribution and dispensing of controlled substances. [16.19.20.3 NMAC - Rp 16.19.20.3 NMAC, 06-26-2018] 16.19.20.4 DURATION: Permanent. [16.19.20.4 NMAC - Rp 16.19.20.4 NMAC, 06-26-2018] 16.19.20.5 EFFECTIVE DATE: June 26, 2018, unless a different date is cited at the end of a section. [16.19.20.5 NMAC - Rp 16.19.20.5 NMAC, 06-26-2018] 16.19.20.6 OBJECTIVE: The objective of Part 20 of Chapter 19 is to protect the public health and welfare of the citizens of New Mexico by controlling and monitoring access to controlled substances and to give notice of the board’s designation of particular substances as controlled substances. [16.19.20.6 NMAC - Rp 16.19.20.6 NMAC, 06-26-2018] 16.19.20.7 DEFINITIONS: [RESERVED] [16.19.20.7 NMAC - Rp 16.19.20.7 NMAC, 06-26-2018] 16.19.20.8 REGISTRATION REQUIREMENTS: Persons required to register: A.
    [Show full text]
  • Cerilliant Corporation
    Federal Register / Vol. 77, No. 71 / Thursday, April 12, 2012 / Notices 21999 Drug Schedule Drug Schedule Administration, that the requirements for such registration pursuant to 21 Etorphine HCl (9059) ................... I Hydromorphone (9150) ................ II U.S.C. 958(a); 21 U.S.C. 823(a); and 21 Codeine methylbromide (9070) .... I Diphenoxylate (9170) ................... II CFR 1301.34(b), (c), (d), (e), and (f) are Dihydromorphine (9145) ............... I Benzoylecgonine (9180) ............... II satisfied. Difenoxin (9168) ........................... I Ethylmorphine (9190) ................... II Heroin (9200) ............................... I Hydrocodone (9193) ..................... II Dated: April 2, 2012. Hydromorphinol (9301) ................. I Levomethorphan (9210) ............... II Joseph T. Rannazzisi, Methyldesorphine (9302) .............. I Levorphanol (9220) ...................... II Deputy Assistant Administrator, Office of Methyldihydromorphine (9304) ..... I Isomethadone (9226) ................... II Diversion Control, Drug Enforcement Morphine methylbromide (9305) .. I Meperidine (9230) ........................ II Administration. Morphine methylsulfonate (9306) I Meperidine intermediate-B (9233) II Morphine-N-oxide (9307) ............. I Metazocine (9240) ........................ II [FR Doc. 2012–8763 Filed 4–11–12; 8:45 am] Myrophine (9308) ......................... I Methadone (9250) ........................ II BILLING CODE 4410–09–P Nicocodeine (9309) ...................... I Methadone intermediate (9254) ..
    [Show full text]
  • University of Groningen Stereoselectivity in the Hepatic Metabolism and Transport of Quaternary Drugs of the Morphinan Type Lant
    University of Groningen Stereoselectivity in the hepatic metabolism and transport of quaternary drugs of the morphinan type Lanting, Aleida Bartha Louisa IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2000 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Lanting, A. B. L. (2000). Stereoselectivity in the hepatic metabolism and transport of quaternary drugs of the morphinan type. s.n. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 24-09-2021 In this thesisthe potential of some quaternaryamine derivativesof the morphinan analoguesdextrorphan, levorphanol, dextromethorphan and levomethorphanas model compoundswas investigatedto study stereoselectivityin hepatic metabolismand transport of cationic drugs.These model compoundspossess a rigid stereochemicalstructure, resulting in major differencesin receptor affinity. We assumedthat the major influenceof the stereochemicalstructure on the receptor level might also causedifferences in carrier-mediatedtransport and biotransformation processes.
    [Show full text]
  • Schedules of Controlled Substances (.Pdf)
    PURSUANT TO THE TEXAS CONTROLLED SUBSTANCES ACT, HEALTH AND SAFETY CODE, CHAPTER 481, THESE SCHEDULES SUPERCEDE PREVIOUS SCHEDULES AND CONTAIN THE MOST CURRENT VERSION OF THE SCHEDULES OF ALL CONTROLLED SUBSTANCES FROM THE PREVIOUS SCHEDULES AND MODIFICATIONS. This annual publication of the Texas Schedules of Controlled Substances was signed by John Hellerstedt, M.D., Commissioner of Health, and will take effect 21 days following publication of this notice in the Texas Register. Changes to the schedules are designated by an asterisk (*). Additional information can be obtained by contacting the Department of State Health Services, Drugs and Medical Devices Unit, P.O. Box 149347, Austin, Texas 78714-9347. The telephone number is (512) 834-6755 and the website address is http://www.dshs.texas.gov/dmd. SCHEDULES Nomenclature: Controlled substances listed in these schedules are included by whatever official, common, usual, chemical, or trade name they may be designated. SCHEDULE I Schedule I consists of: -Schedule I opiates The following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, if the existence of these isomers, esters, ethers, and salts are possible within the specific chemical designation: (1) Acetyl-α-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N- phenylacetamide); (2) Acetylmethadol; (3) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide); (4) Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide) (Other name:
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley Et Al
    US 2014O144429A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley et al. (43) Pub. Date: May 29, 2014 (54) METHODS AND DEVICES FOR COMPOUND (60) Provisional application No. 61/887,045, filed on Oct. DELIVERY 4, 2013, provisional application No. 61/831,992, filed on Jun. 6, 2013, provisional application No. 61/794, (71) Applicant: E-NICOTINE TECHNOLOGY, INC., 601, filed on Mar. 15, 2013, provisional application Draper, UT (US) No. 61/730,738, filed on Nov. 28, 2012. (72) Inventors: Martin Wensley, Los Gatos, CA (US); Publication Classification Michael Hufford, Chapel Hill, NC (US); Jeffrey Williams, Draper, UT (51) Int. Cl. (US); Peter Lloyd, Walnut Creek, CA A6M II/04 (2006.01) (US) (52) U.S. Cl. CPC ................................... A6M II/04 (2013.O1 (73) Assignee: E-NICOTINE TECHNOLOGY, INC., ( ) Draper, UT (US) USPC ..................................................... 128/200.14 (21) Appl. No.: 14/168,338 (57) ABSTRACT 1-1. Provided herein are methods, devices, systems, and computer (22) Filed: Jan. 30, 2014 readable medium for delivering one or more compounds to a O O Subject. Also described herein are methods, devices, systems, Related U.S. Application Data and computer readable medium for transitioning a Smoker to (63) Continuation of application No. PCT/US 13/72426, an electronic nicotine delivery device and for Smoking or filed on Nov. 27, 2013. nicotine cessation. Patent Application Publication May 29, 2014 Sheet 1 of 26 US 2014/O144429 A1 FIG. 2A 204 -1 2O6 Patent Application Publication May 29, 2014 Sheet 2 of 26 US 2014/O144429 A1 Area liquid is vaporized Electrical Connection Agent O s 2.
    [Show full text]
  • 2005 House Bill Text for HB0713
    AN ACT RELATING TO CONTROLLED SUBSTANCES; MAKING IT A CRIME TO DISTRIBUTE CERTAIN RAPE DRUGS WITHOUT THE RECIPIENT'S KNOWLEDGE; PROVIDING PENALTIES FOR DISTRIBUTING A RAPE DRUG WITHOUT THE RECIPIENT'S KNOWLEDGE AND FOR POSSESSION OF RAPE DRUGS; RECONCILING MULTIPLE AMENDMENTS TO LAWS 1990. BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF NEW MEXICO: Section 1. Section 30-31-1 NMSA 1978 (being Laws 1972, Chapter 84, Section 1) is amended to read: "30-31-1. SHORT TITLE.--Chapter 30, Article 31 NMSA 1978 may be cited as the "Controlled Substances Act"." Section 2. Section 30-31-6 NMSA 1978 (being Laws 1972, Chapter 84, Section 6, as amended) is amended to read: "30-31-6. SCHEDULE I.--The following controlled substances are included in Schedule I: A. any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters and ethers, unless specifically exempted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation: (1) acetylmethadol; (2) allylprodine; (3) alphacetylmethadol; (4) alphameprodine; HB 713 Page 1 (5) alphamethadol; (6) benzethidine; (7) betacetylmethadol; (8) betameprodine; (9) betamethadol; (10) betaprodine; (11) clonitazene; (12) dextromoramide; (13) dextrorphan; (14) diampromide; (15) diethylthiambutene; (16) dimenoxadol; (17) dimepheptanol; (18) dimethylthiambutene; (19) dioxaphetyl butyrate; (20) dipipanone; (21) ethylmethylthiambutene; (22) etonitazene; (23) etoxeridine; (24) furethidine; (25) hydroxypethidine; (26) ketobemidone; (27) levomoramide; (28) levophenacylmorphan; (29) morpheridine; HB 713 Page 2 (30) noracymethadol; (31) norlevorphanol; (32) normethadone; (33) norpipanone; (34) phenadoxone; (35) phenampromide; (36) phenomorphan; (37) phenoperidine; (38) piritramide; (39) proheptazine; (40) properidine; (41) racemoramide; and (42) trimeperidine; B.
    [Show full text]
  • Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority
    Chapter 8 – Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority This rule is established under the authority of 18 V.S.A. §§ 4201 and 4202 which authorizes the Vermont Board of Health to designate regulated drugs for the protection of public health and safety. 2.0 Purpose This rule designates drugs and other chemical substances that are illegal or judged to be potentially fatal or harmful for human consumption unless prescribed and dispensed by a professional licensed to prescribe or dispense them, and used in accordance with the prescription. The rule restricts the possession of certain drugs above a specified quantity. The rule also establishes benchmark unlawful dosages for certain drugs to provide a baseline for use by prosecutors to seek enhanced penalties for possession of higher quantities of the drug in accordance with multipliers found at 18 V.S.A. § 4234. 3.0 Definitions 3.1 “Analog” means one of a group of chemical components similar in structure but different with respect to elemental composition. It can differ in one or more atoms, functional groups or substructures, which are replaced with other atoms, groups or substructures. 3.2 “Benchmark Unlawful Dosage” means the quantity of a drug commonly consumed over a twenty-four hour period for any therapeutic purpose, as established by the manufacturer of the drug. Benchmark Unlawful dosage is not a medical or pharmacologic concept with any implication for medical practice. Instead, it is a legal concept established only for the purpose of calculating penalties for improper sale, possession, or dispensing of drugs pursuant to 18 V.S.A.
    [Show full text]